# Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

> **NCT04404595** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CARsgen Therapeutics Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Gastric Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** CT041

## Key facts

- **NCT ID:** NCT04404595
- **Lead sponsor:** CARsgen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-23
- **Primary completion:** 2025-06-01
- **Final completion:** 2035-09-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04404595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04404595, "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04404595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*